EP-0108A is a moderation selectively BRD4 BD2 inhibitor with potential AML tumor suppression

Author:

Li Li12,Zhu Hui2,Liu Shuang2

Affiliation:

1. Department of Biophysics, School of Life Science and Technology, University of Electronic Science and Technology of China

2. Drug Screening Department, Chengdu Easton Biopharmaceuticals Co., Ltd., Chengdu, China

Abstract

Acute myeloid leukemia is the most common type of acute leukemia in adults. The epigenetic molecule BRD4 is a member of the bromodomain and extra-terminal family and plays an important role in the occurrence and development of tumors. BRD4 is essential for oncogene expression, including c-Myc. So, BRD4 inhibition is considered as an effective strategy for the treatment of hematological and solid malignancies. In recent years, several small molecule inhibitors targeting BRD4 have been developed. However, these inhibitors had excessive hematological toxicity due to the lack of specific binding to BD1 and BD2 domains of BRD4, while other inhibitors with high selectivity lose their antitumor efficacy. To balance the relationship between efficacy and safety, we developed EP-0108A, a BRD4 inhibitor with moderate selectivity for the BD2 domain over BD1 domain of BRD4. Our results show that EP-0108A has antitumor effects in MV4-11 and Kasumi-1 cell line-derived xenograft mouse models without significant effects on heart or breathing safe in rats and Beagle dogs. In repeated dose toxicity studies, EP-0108A showed reversible hematological and gastrointestinal toxicity in both rats and dogs. Our findings indicate that EP-0108A has the potential to be a new therapeutic agent for the treatment of cancer.

Funder

Chengdu Easton Biopharmaceuticals Co., Ltd

Publisher

Ovid Technologies (Wolters Kluwer Health)

Reference24 articles.

1. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia.;Ley;N Engl J Med,2013

2. Epigenetics and approaches to targeted epigenetic therapy in acute myeloid leukemia.;Wouters;Blood,2016

3. The role of human bromodomains in chromatin biology and gene transcription.;Sanchez;Curr Opin Drug Discov Devel,2009

4. Bromodomain interactions with acetylated histone 4 peptides in the BRD4 tandem domain: effects on domain dynamics and internal flexibility.;Wernersson;Biochemistry,2022

5. Bromodomain biology and drug discovery.;Zaware;Nat Struct Mol Biol,2019

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3